

## ONCOLOGY



**Working together with our collaboration partners, Boehringer Ingelheim is leading the way in the search for novel therapeutic concepts, drug candidates and treatment modalities in oncology and cancer immunology.**

**Our Oncology Partnering Focus**

We are seeking in-licensing and collaborative opportunities at discovery, pre-clinical and clinical stages, for therapeutic programs in our interest areas.

**Cancer cell-directed therapies:**

- Growth signalling e.g. KRAS, WNT, MYC, RTKs
- Cell death and DNA damage control pathways
- Novel ADC targets
- Transcriptional regulation

**Immune cell-directed therapies:**

- Myeloid cell-modulating therapies
- Tumor stromal concepts and targets
- Novel tumor antigen identification platforms, including neoantigens

For more information please contact :

Dr. Namiko Yamashita <[namiko.yamashita@boehringer-ingelheim.com](mailto:namiko.yamashita@boehringer-ingelheim.com)>

Dr. Takeshi Kono <[takeshi.kono@boehringer-ingelheim.com](mailto:takeshi.kono@boehringer-ingelheim.com)>